Tavo Biotherapeutics Announces $17 Million Series A Financing to Advance Novel Therapies in Glaucoma and Retinal Disease
LAGUNA BEACH, Calif., June 2, 2026 /PRNewswire/ -- Tavo Biotherapeutics today announced the successful closing of a $17 million Series A financing led by Pureos Bioventures with participation by Polaris Partners and continued support from existing investor Tau Capital. The proceeds will...
LAGUNA BEACH, Calif., June 2, 2026 /PRNewswire/ -- Tavo Biotherapeutics today announced the successful closing of a $17 million Series A financing led by Pureos Bioventures with participation by Polaris Partners and continued support from existing investor Tau Capital. The proceeds will...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.